Insider Transactions in Q1 2026 at Ptc Therapeutics, Inc. (PTCT)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 12
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,024
-1.26%
|
$79,872
$78.7 P/Share
|
|
Jan 09
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
2,314
-0.68%
|
$180,492
$78.56 P/Share
|
|
Jan 09
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,722
-2.08%
|
$132,594
$77.41 P/Share
|
|
Jan 08
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
59
-0.86%
|
$4,484
$76.45 P/Share
|
|
Jan 08
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
881
-0.76%
|
$66,956
$76.45 P/Share
|
|
Jan 08
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
4,033
-1.15%
|
$306,508
$76.69 P/Share
|
|
Jan 08
2026
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
866
-0.93%
|
$65,816
$76.45 P/Share
|
|
Jan 08
2026
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,514
-0.63%
|
$191,064
$76.45 P/Share
|
|
Jan 08
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,602
-1.78%
|
$349,752
$76.62 P/Share
|
|
Jan 08
2026
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,034
-1.4%
|
$78,584
$76.45 P/Share
|
|
Jan 07
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
52
-0.75%
|
$4,004
$77.48 P/Share
|
|
Jan 07
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,026
-0.88%
|
$79,002
$77.48 P/Share
|
|
Jan 07
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
4,879
-0.58%
|
$375,683
$77.87 P/Share
|
|
Jan 07
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,376
+1.38%
|
$128,288
$38.1 P/Share
|
|
Jan 07
2026
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
642
-0.68%
|
$49,434
$77.48 P/Share
|
|
Jan 07
2026
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,016
-0.75%
|
$232,232
$77.48 P/Share
|
|
Jan 07
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,352
-1.52%
|
$104,104
$77.48 P/Share
|
|
Jan 07
2026
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,235
-1.65%
|
$95,095
$77.45 P/Share
|
|
Jan 06
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
54
-0.78%
|
$4,104
$76.95 P/Share
|
|
Jan 06
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,279
-1.08%
|
$97,204
$76.95 P/Share
|
|
Jan 06
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,739
-1.44%
|
$132,164
$76.95 P/Share
|
|
Jan 06
2026
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,340
-1.41%
|
$101,840
$76.95 P/Share
|
|
Jan 06
2026
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,149
-1.27%
|
$391,324
$76.95 P/Share
|
|
Jan 06
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,789
-1.97%
|
$135,964
$76.95 P/Share
|
|
Jan 06
2026
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,139
-2.31%
|
$162,564
$76.95 P/Share
|
|
Jan 06
2026
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,381
-1.81%
|
$104,956
$76.95 P/Share
|
|
Jan 05
2026
|
Emma Reeve |
SELL
Open market or private sale
|
Direct |
734
-6.44%
|
$55,784
$76.0 P/Share
|
|
Jan 05
2026
|
Emma Reeve |
BUY
Exercise of conversion of derivative security
|
Direct |
734
+6.05%
|
$33,764
$46.54 P/Share
|
|
Jan 05
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
2,266
-0.62%
|
$169,950
$75.94 P/Share
|
|
Jan 05
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,266
+1.81%
|
$88,374
$39.42 P/Share
|
|
Jan 02
2026
|
Glenn Jr Md Phd Steele |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.09%
|
-
|
|
Jan 02
2026
|
Glenn Jr Md Phd Steele |
SELL
Open market or private sale
|
Direct |
12,000
-39.34%
|
$912,000
$76.35 P/Share
|
|
Jan 02
2026
|
Glenn Jr Md Phd Steele |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+28.24%
|
$360,000
$30.86 P/Share
|
|
Jan 02
2026
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
63,000
+13.46%
|
-
|
|
Jan 02
2026
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+17.79%
|
-
|
|
Jan 02
2026
|
Michael Schmertzler |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+4.67%
|
-
|
|
Jan 02
2026
|
Allan Steven Jacobson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.72%
|
-
|
|
Jan 02
2026
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Jan 02
2026
|
David P Southwell |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+16.1%
|
-
|
|
Jan 02
2026
|
Alethia Young |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.96%
|
-
|
|
Jan 02
2026
|
Jerome B Zeldis |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.09%
|
-
|
|
Jan 02
2026
|
Emma Reeve |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+27.27%
|
-
|
|
Jan 02
2026
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+12.33%
|
-
|
|
Jan 02
2026
|
Eric Pauwels CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+18.08%
|
-
|
|
Jan 02
2026
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+16.44%
|
-
|
|
Jan 02
2026
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,250
+14.79%
|
-
|
|
Jan 02
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
520
+6.96%
|
-
|
|
Jan 02
2026
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+12.88%
|
-
|
|
Jan 02
2026
|
Mary L. Smith |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+15.5%
|
-
|